Simcere Pharmaceutical Group Limited

2096

HK0000658531

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:09 16/07/2024 BST			5-day change	1st Jan Change
5.62 ^HKD	-0.88%		+1.63%	-16.49%

07-11	Simcere Pharmaceutical Group COVID-19 Drug Gets Chinese Regulator's Marketing Approval	MT
07-11	Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug	CI

Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024

June 14, 2024 at 11:51 am

Simcere Pharmaceutical Group Limited, at its AGM held on 14 June 2024, approved final dividend of RMB 0.16 per share for the year ended December 31, 2023. Ex-dividend date 18 June 2024, Record date 25 June 2024 and Payment date 15 July 2024.

Latest news about Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group COVID-19 Drug Gets Chinese Regulator's Marketing Approval	07-11	MT
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug	07-10	CI
Simcere-Mabpharm Cancer Drug Gets Marketing Approval in China	06-25	MT
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China	06-25	CI
Jiaxing Andicon Biotech Co., Ltd. announced that it has received CNY 200 million in funding from a group of investors	06-24	CI
Simcere Pharmaceutical Group Limited commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.	06-18	CI
Simcere Pharma Shareholders Approve Up to 500 Million Yuan Share Buyback	06-17	MT
Simcere Pharmaceutical Group Limited Announces Management Changes	06-14	CI
Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	06-14	CI
Simcere Pharmaceutical Group Limited's Equity Buyback announced on June 29, 2023, has expired.	06-13	CI
Simcere Pharmaceutical’s Cancer Drug Shows Positive Results	06-03	MT
Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting	06-03	MT
Simcere Pharmaceutical Group Limited Announces Results of the Phase III Clinical Trial of ENZESHU for the Treatment Ofplatinum-Resistant Ovarian Cancer Were Presented at the ASCO Annual Meeting	06-02	CI
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China	05-31	CI
Simcere Pharmaceutical Group's Hypnotic Drugs Gets the Nod from Hong Kong Authorities	05-23	MT
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong	05-22	CI
Simcere Pharmaceutical’ Profit Down 23% in 2023	04-25	MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	04-10	MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	04-09	CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	03-21	MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	03-20	CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	03-18	MT
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	03-15	CI
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	03-13	MT

Chart Simcere Pharmaceutical Group Limited

Duration

Period

Chart Simcere Pharmaceutical Group Limited

More charts

Company Profile

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Simcere Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.229 CNY

Average target price

8.004 CNY

Spread / Average Target

+53.07%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SIMCERE PHARMACEUTICAL GROUP LIMITED	-16.49%	1.84B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.54B
OTSUKA HOLDINGS CO., LTD.	+34.52%	24.51B
SANDOZ GROUP AG	+27.12%	16.48B
CIPLA LIMITED	+21.19%	14.66B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.3B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.15%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals